Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study - Wikidata - wikimedia - TriplyDB

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

http://www.wikidata.org/entity/Q24670020

about

Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia To wake up cancer stem cells, or to let them sleep, that is the question Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.Challenges in treating older patients with acute myeloid leukemia.Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Mesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicine ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML.Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission.Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma.Role of cytokines in the treatment of acute leukemias: a review.Current therapeutic strategies for acute myeloid leukaemia.Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.Senior adult oncology.Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice.Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials.Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma.Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy.Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors.Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated Fusarium solani infection.Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.Systemic chemotherapy with pronounced efficacy and neutropenia in a granulocyte-colony stimulating factor-producing advanced gastric neuroendocrine carcinoma.Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Onc A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders.Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials.Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.Improving Immunotherapy Through Glycodesign

P2860

Q24202698-B8C5350F-FE32-4C45-AE3A-884B6FDBBE56 Q24234458-7D935472-9D20-440B-89D6-58B1FC5E13E3 Q26749632-E2CB5CAB-651C-4114-9450-0EF5CF2B4475 Q33539387-A765260C-738B-47B1-8918-006AE001F006 Q33985549-7F4C1F85-59F7-47D1-AE4E-6A571D0EEF9D Q34655572-1A7444FC-3989-47E9-98B6-13FCED767389 Q35122122-8F871A88-4D68-45DA-BFA9-15EED4C89992 Q35193725-6AD7F67D-8A7E-4714-9B5F-3DAEB280CAB5 Q35546219-A13F9FC5-0BAB-42FA-94F4-1238E417D0C6 Q35717841-66A476FB-A8F1-4AAA-8AFC-227F0E310597 Q35944724-351AC739-DAA7-4096-9568-48F5E2BF87E9 Q36196735-FDAEB18C-A96B-4281-951B-0D746BD1CDA6 Q36393320-1F0FA39D-2039-484E-9F28-7757036C7A01 Q36405044-06BFB80A-404B-46FA-9431-13A690272BF1 Q36539598-10C2216E-41D0-44C6-9DCC-B62408A413F2 Q36761725-5C3C351F-9119-4BCB-A453-B5A461B111CB Q36851424-1AC2264B-CA16-4C4B-8545-A6B9A1370CE0 Q37026715-6259E054-4FB7-453E-B209-02823FC5A378 Q37323006-5CCFD076-B089-4FE5-B61E-B41BA667639A Q37379434-8732BFD4-B7F5-467A-8F1B-B9CBFDCAA9C2 Q37381690-3AE18BFF-B988-475B-A048-DF527E35B7A7 Q37788578-3B7E1E55-3D45-47CC-BF37-89F134393EB0 Q37810266-BE319BEB-E151-431E-954B-C96D34E45FAA Q37866758-4C4BF98C-9D09-4310-91D0-43B004106DB9 Q38269589-CDE409B4-EA0C-4D3B-BE68-A0CA651185BF Q38542828-409AE69C-8B70-46DB-B6CC-1F7BC6805EB6 Q39031745-82FF82A4-6809-4F65-9F62-AA6F2E6A8925 Q39311595-54690B00-58EC-42D4-9C54-4B9B71F95CB1 Q39361086-48E228FC-31CF-4331-A303-1395BF68E299 Q40099377-399765CD-1188-4692-8B68-04E5B79D34E0 Q40138696-656ECCAB-0ABE-4FCA-9E81-308378A122DF Q40256523-8ACE6B82-815D-4AEE-8F10-AF0635C6C3A1 Q41142382-B11A2DA6-8970-4CED-82CB-4E7D0D9B2E79 Q42223844-A02631B1-8B90-44FC-908F-940828AF6217 Q43181954-20F39CD5-D573-462E-BA66-DE8D6675B31C Q47235713-F0784CE4-4D7C-4E2C-870F-EAC0CEFB534A Q51784425-A641212D-BB30-4C99-89F5-E8903BB43B37 Q52770446-25CFF675-5580-4307-881B-90B247167050 Q59132146-DCEEB057-1D18-46BD-9498-1B559B6F2391

P2860

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

http://www.wikidata.org/entity/Q24670020

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@ast

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@en

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@nl

type

label

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@ast

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@en

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@nl

prefLabel

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@ast

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@en

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@nl

P1433

Q24670020-6962ADE5-E4A9-4F4B-A526-8D4D92736C11

P1476

Q24670020-81484BD9-E65F-4804-968F-630B4ED6AB65

P2093

Q24670020-1ACF8256-7B33-460D-8D7A-8F29D1520766

Q24670020-300BA692-E992-4A99-8274-310E118A9179

Q24670020-311B0CE0-25EB-4AD2-AC12-747E3CA96818

Q24670020-31FA40EC-818C-4338-ADBB-8D4CB8BE5B2F

Q24670020-36251E01-7B36-4440-BDED-5F1160EFF2AF

Q24670020-3CC1D164-D6F2-48B9-8370-7A36DB9E5E2A

Q24670020-4EFB933F-9628-41A7-B985-AF25C70281D9

Q24670020-5A562BFF-142B-41C8-80DC-B0B44CBCB39D

Q24670020-7B7D5803-F65C-46F7-B39F-C8B39114748C

Q24670020-8FAF9C58-37F9-478B-BC93-D316E1F2A1E9

P2860

Q24670020-201CF601-1C54-48B6-96C5-339F79644C77

Q24670020-25AF708D-2293-48C5-AD17-1A4B7C9A01DE

Q24670020-299DC478-0BE4-4EA1-95DD-D2B9500A69B0

Q24670020-36C70BD1-A2CC-4477-9BFC-38E464C92B5A

Q24670020-3CE51423-5892-4DD4-B40F-7B2F769CA052

Q24670020-441190E9-CAB8-4092-A5CB-E3C230AD23C6

Q24670020-44D7DA1B-934D-44D9-953A-C409C1734E41

Q24670020-5CCE0E12-F916-44DF-8717-0FD299DD16B9

Q24670020-5D02ADA8-EBBC-41E8-9A07-8014B1DDAB7E

Q24670020-68DEBF0F-1125-43C6-BF53-B132C5CB3A9A

P304

Q24670020-E8384234-802E-4242-A5DE-213E98CEDD37

P31

Q24670020-82D626E9-EDBA-4100-AB0A-95005D0B0E97

P3181

Q24670020-CB83B530-76B9-4D7C-BD98-AB54A7751B5A

P356

Q24670020-78FD9F28-C655-4290-873D-3CF25ED52526

P407

Q24670020-9D1CD3B9-D6BB-4B57-99FA-8D68B1C16317

P433

Q24670020-607FBE48-6440-41D7-B42F-5D76E7EE4142

P478

Q24670020-1A302F29-372C-479E-A51A-49E0FF47475D

P50

Q24670020-27258695-C12B-4757-A10D-E5D8723EFF8C

Q24670020-5D733F5B-5843-4AD3-BE5B-5AAB0567F9E5

Q24670020-6902E6C8-AFAB-4B9A-B756-F6608AEAE0FF

Q24670020-7F518D64-89B0-4878-A824-B3B49F6FAA8D

P577

Q24670020-AEB3A153-5CD1-4053-9053-03A7D1E2611D

P5875

Q24670020-9CF75E29-F166-42DA-B529-2CFE70EF71B5

P698

Q24670020-F497C6A1-9584-4255-B36B-8ED3B9E61C3C

P921

Q24670020-09C88908-A6F1-4507-BDA8-936FC6E34986

Q24670020-478FEA96-3C8C-414B-925C-72C039C3C9D2

Q24670020-7D317B0A-CBB6-44EF-AA59-53B9F5131B05

Q24670020-AB83CEDA-9606-4E8E-ADC8-4A3A021B06C1

P932

Q24670020-924AF900-3C75-48F9-B12C-2DB129A5645C

P3181

P356

BLOOD-2004-09-3728

P1433

P1476

Use of glycosylated recombinan ...... 13, a randomized phase-3 study

@en

P2093

Claudio Denzlinger

http://www.w3.org/2001/XMLSchema#string

EORTC/GIMEMA Leukemia Group

http://www.w3.org/2001/XMLSchema#string

Filip Beeldens

http://www.w3.org/2001/XMLSchema#string

Francesco Ricciuti

http://www.w3.org/2001/XMLSchema#string

Franco Mandelli

http://www.w3.org/2001/XMLSchema#string

Francois Lefrère

http://www.w3.org/2001/XMLSchema#string

George Fillet

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Marie

http://www.w3.org/2001/XMLSchema#string

Marco Casini

http://www.w3.org/2001/XMLSchema#string

Pietro Leoni

http://www.w3.org/2001/XMLSchema#string

P2860

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML).

A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).

Management of acute myeloid leukemia in elderly patients.

Concurrent use of growth factors and chemotherapy in acute leukemia.

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

P304

27-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2085504

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2004-09-3728

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7973475

http://www.w3.org/2001/XMLSchema#string

P698

15761020

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895135

http://www.w3.org/2001/XMLSchema#string